GVK BIO signs pact with US-based Aragen for acquisition

GVK BIO, a leading small-molecule Contract Research Organisation (CRO) today announced that it signed an agreement to acquire Aragen Bioscience Inc, a privately-held US-based, pre-clinical CRO.
Without disclosing the financial details, a press release from GVK Bio said the deal enables GVK BIO to expand its service offering to a broader base of organisations and gives expertise in biologics services besides significant US presence.
The acquisition provides Aragen with the ability to expand its service offerings, access to GVK BIO's global sales force and access to new markets, the release said.
D S Brar, Chairman, GVK BIO said as an increasing number of biotech and pharmaceutical companies focus on protein-based therapeutics and bio-similars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO's ability to offer high quality R&D services to the industry from a seamless integrated platform.

Rick Srigley, President & CEO, Aragen Bioscience said Aragen's scientific excellence and expertise in large-molecule R&D services combined with GVK BIO's scale, resources, and global reach will create significant synergies for both companies.